Desang diabetes magazine diabetes news

NEWS

ELI LILLY TEAMS

UP WITH

DEXCOM

As reported by Nick Paul Taylor, for Fierce

Biotech, Eli Lilly is working on insulin

delivery devices and has teamed up

with Dexcom to add continuous glucose

monitoring systems to its arsenal. Lilly

has quietly worked on an automated,

wearable insulin delivery device and

smart pen injector at a lab it opened in

2015, The Wall Street Journal reported.

"Do we want to be just an insulin provider

that just goes into a system, or do we

want to be the integrator of the system?"

Enrique Conterno, head of Lilly's diabetes

business, told the WSJ. "To me, it's clear

where the business is going."

As Conterno sees it, failing to diversify

beyond insulin and into drug delivery

systems would lead to Lilly's diabetes

business becoming "obsolete." However,

all R&D is something of a risk, especially

because it moves Lilly onto unfamiliar

territory colonized by big businesses.

Medtronic won FDA approval for an

automated insulin delivery device last year

and a clutch of other medical technology

companies are giving chase.

Lilly's entrant to the race, at least at

the prototype stage, is a "disk about

the size of a shoe-polish tin," the WSJ

reports, which contains a three-day

supply of insulin that is pumped into the

patient as needed. The deal with Dexcom

gives Lilly access to continuous glucose

monitoring devices that provide data to

support this automated delivery process.

Last year Eli LIlly quietly bought Class AP

for its algorithms that decide on the insulin

injection regimen. The next step is to

move the most advanced of the devices

into the clinic, something Lilly expects to

do by the end of the year. Lilly thinks it will

take two to three years to get the first of

its devices to market.

www.fiercebiotech.com

As reported by by Viswanath Pilla for

moneycontrol.com, Biopharmceutical firm

Biocon gains funding from JDRF to test its

oral insulin candidate Tregopil on Type 1

diabetes patients.

"This collaboration with Biocon is

a part of JDRF's Industry Discovery

and Development Partnership

(IDDP) programme, through which

JDRF provides financial support to

accelerate breakthrough research in

T1D management," Biocon said in a

statement, but did not disclose the

amount of funding.

As per the agreement JDRF (Juvenile

Diabetes Research Foundation) will fund

Biocon's global multiple ascending dose

study of oral insulin drug candidate to

evaluate the safety and tolerability in

people with Type 1 diabetes. "With this

proposed clinical study, we hope to build

on the extremely promising data that we

have generated so far through previous

human trials with Tregopil,"said Kiran

INSULIN IN PILL FORM

As reported in Fierce Biotech, in the US,

Semma Therapeutics has raised $114

million to take a potentially-curative Type 1

diabetes cell therapy through clinical proof

of concept. The round positions Semma to

start learning whether its insulin-producing

cells can control blood sugar levels in

diabetics. Cambridge, Massachusettsbased Semma set up shop in 2014 to

capitalize on a breakthrough that enabled

the production of pancreatic beta cells

from undifferentiated pluripotent stem

cells. The investment will enable Semma

to test whether its preclinical work will

translate into early clinical success.

Semma is advancing toward the

clinic on the back of research into how to

administer beta cells so they deliver insulin

SEMMA'S CELL THERAPY 'CURE'

Mazumdar-Shaw, CMD, Biocon.

Biocon has developed new

formulation of insulin to be delivered

through a pill instead of an injection as

it is taken now. Insulin delivered through

a pill is considered more convenient,

safe and effective; however, the success

has been elusive so far as insulin rapidly

degrades in the stomach and the upper

portion of the small intestine, making it

almost impossible to deliver orally. Danish

company Novo Nordisk withdrew from

oral insulin citing commercial viability last

year. But based on the positive outcomes

of it own trials, Biocon has decided to

advance this research asset through

clinical trials for validation in a larger

patient cohort and has also filed a Clinical

Trial Application for a Phase II/III study

with Insulin Tregopil in people with Type

2 diabetes

www.moneycontrol.com

to the body without being rejected by the

immune system. That challenge has been

a focal point of research over the past two

years at Semma, which began life with an

understanding of how to produce beta

cells, at least at lab scale, but without a

device in which to encapsulate them.

"Semma's scientists have very

effectively dedicated themselves to

systems that reliably generate cells

indistinguishable from human pancreatic

beta cells and to the invention of novel

devices that are immunologically

protective and surgically practical,"

Douglas Melton, Ph.D., Semma founder

and co-author of the beta cell paper that

triggered its creation, said in a statement.

www.fiercebiotech.com

Index

  1. Desang diabetes magazine diabetes information
  2. Abbott Freestyle Libre, Flash Glucose Monitoring, blood testing without lancets
  3. Desang diabetes magazine diabetes information, Sue Marshall
  4. Omnipod insulin pump uk
  5. Desang diabetes magazine diabetes news
  6. Desang diabetes kitbags
  7. Desang diabetes magazine diabetes news
  8. Diabetes technology as body art from Harvard
  9. Dexcom CGM, continuous glucose monitoring
  10. International Diabetes Federation World Diabetes Day 2017
  11. International Diabetes Federation World Diabetes Day 2017, Ascensia, Dexcom, Sanofi every1matters
  12. Accu-Chek Mobile blood glucose system
  13. Accu-Chek Mobile blood glucose system
  14. Medtronic's My Pump Choice hub
  15. Ascensia type 2 diabetes digital challenge
  16. Page 0016
  17. Diabetes food news
  18. Brindisa Spanish foods
  19. Brindisa Spanish foods, Nife is Life Italian foods, Steenbergs spices
  20. Craved craft British food and Flaming Licks fiery foods
  21. Ascensia Contour Diabetes blood test meters
  22. Bloom gin, honeybee gin, Luscombe drinks, Lyme bay wines
  23. Demuth's cookery school, Bateaux Windsor
  24. Diabetes UK, mental health for people with diabetes
  25. Diabetes UK, mental health for people with diabetes
  26. Neuropad diabetes footcare
  27. Medtronic i-Port Advance insulin injecting aid
  28. Fleur Brown, Beat Chronic Diseases, the nutrition solution
  29. Fitlegs diabetic socks
  30. Making Carbs Count swedes
  31. Making Carbs Count swedes, think vegetables
  32. Accu-Chek Insight insulin pump
  33. Accu-Chek Insight insuiln pump
  34. Free diabetes magazine, living with diabetes, the diabetic diet, carb counting

Related Issues

powered by PageTiger